UGCG and ovarian carcinoma: To validate the developed methodology for GCS activity assessment, we used drug-sensitive A2780 and drug-resistant NCI/ADR-RES ovarian cancer cell lines, as previous studies indicated that higher levels of GCS constitute the basis of drug resistance in cells of the latter line26, 28, 39.